Search results
Results from the WOW.Com Content Network
Given the success of the IPI for intermediate grade lymphomas, an effort was undertaken to develop a similar prognostic index for the most common low-grade lymphoma, follicular lymphoma. The prognostic factors that emerged from this were: age, stage, number of lymph node areas involved, serum hemoglobin level, and serum LDH.
In general, overall survival rates after 5, 10, and 15 years of treatment have been 95%, 85%, and 78% respectively. While the response to these therapeutic regimens has been very good, ~33% of treated patients have experience a recurrence of their lymphoma in the salivary/lacrimal glands, lymph nodes, or other sites. [20]
In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 (5.4%) died. [4] [5] In the United States, 2.1% of people are affected at some point in their life. [2] The most common age of diagnosis is between 65 and 75 years old. [2] The five-year survival rate in the United States is 71%. [2]
The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 85%, [4] while that for non-Hodgkin lymphomas is 69%. [15] Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. [16] They make up 3–4% of all cancers, making them as a group the seventh-most-common form.
These earlier used chemotherapy regimens (e.g. the CHOP regimen consisting of three chemotherapy drugs (cyclophosphamide, hydroxydoxorubicin, and oncovin) plus a glucocorticoid, either prednisone or prednisolone) [7] achieve complete response rates of 48% to 85%, 3-year overall survival rates of 50% to 64%, and 5-year overall survival rates of ...
The Organization (2016) also termed a third type of intestinal T cell lymphoma that could not be classified as ATL or MEITL as intestinal T cell lymphoma, not otherwise specified. [6] MEITL is a highly aggressive GI tract lymphoma [7] which typically has had very short survival times following its diagnosis. [2]
In childhood, T-cell acute lymphoblastic leukemia (T-ALL) patients can expect a 5-year event-free survival (EFS) rate of 70% and an overall survival (OS) rate of 80%. [1] Among the approximately 25% of children who relapse, survival rates drop to 30-50%, with patients generally showing a much poorer prognosis. [ 1 ]
A review of 105 PEL cases reported median survival times, 1-year, 3-year, and 5-year survival rates of 4.8 months, 30%, 18%, and 17%, respectively. In this study, patients with advanced Ann Arbor Stage III or IV disease had a particularly poor survival rate at 1 year of 25%; this compared to a rate of 42% for patients with stage I or II disease ...